Evidence map›Paper›PMID 37716353›Full record

ReviewCell reports. Medicine2023

The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring.

Syeda Maheen Batool, Anudeep Yekula, Prerna Khanna, Tiffaney Hsia, Austin S Gamblin, Emil Ekanayake, Ana K Escobedo, Dong Gil You, Cesar M Castro, Hyungsoon Im and 38 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 3 pooled it
43.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 3 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 13 institutions in 1 country.

Syeda Maheen BatoolMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Anudeep YekulaMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Prerna KhannaMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Tiffaney HsiaMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Austin S GamblinMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Emil EkanayakeMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ana K EscobedoMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Dong Gil YouMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Cesar M CastroMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Hyungsoon ImMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Tugba KilicMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Michelle Andrea GarlinMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Johan SkogExosome Diagnostics Inc., Waltham, MA, USA.
Daniela M DinulescuBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jonathan DudleyJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Nishant AgrawalUniversity of Chicago School of Medicine, Chicago, IL, USA.
Jordan ChengUniversity of California Los Angeles, Los Angeles, CA, USA.
Fereidoun AbtinUniversity of California Los Angeles, Los Angeles, CA, USA.
Denise R AberleUniversity of California Los Angeles, Los Angeles, CA, USA.
David ChiaUniversity of California Los Angeles, Los Angeles, CA, USA.
David ElashoffUniversity of California Los Angeles, Los Angeles, CA, USA.
Tristan GrognanUniversity of California Los Angeles, Los Angeles, CA, USA.
Kostyantyn KrysanUniversity of California Los Angeles, Los Angeles, CA, USA.
Scott S OhUniversity of California Los Angeles, Los Angeles, CA, USA.
Charles StromUniversity of California Los Angeles, Los Angeles, CA, USA.
Michael TuLiquid Diagnostics LLC., Los Angeles, CA, USA.
Fang WeiUniversity of California Los Angeles, Los Angeles, CA, USA.
Rena R XianJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Steven J SkatesMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
David Y ZhangRice University, Houston, TX, USA.
Thi TrinhYale University School of Medicine, New Haven, CT, USA.
Mark WatsonWashington University School of Medicine, St. Louis, MO, USA.
Rebecca AftWashington University School of Medicine, St. Louis, MO, USA.
Siddarth RawalWashington University School of Medicine, St. Louis, MO, USA; Circulogix Inc., St. Louis, MO, USA.
Ashutosh AgarwalUniversity of Miami, Miami, FL, USA.
Susan B KesmodelUniversity of Miami, Miami, FL, USA.
Changhuei YangCalifornia Institute of Technology, Pasadena, CA, USA.
Cheng ShenCalifornia Institute of Technology, Pasadena, CA, USA.
Fred H HochbergScintillon Institute, La Jolla, CA, USA.
David T W WongUniversity of California Los Angeles, Los Angeles, CA, USA.
Abhijit A PatelYale University School of Medicine, New Haven, CT, USA.
Nickolas PapadopoulosJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Chetan BettegowdaJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Richard J CoteWashington University School of Medicine, St. Louis, MO, USA; Circulogix Inc., St. Louis, MO, USA.
Sudhir SrivastavaCancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Hakho LeeMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Bob S CarterMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Leonora BalajMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: balaj.leonora@mgh.harvard.edu.
Harvard University · USUniversity of California, Los Angeles · USJohns Hopkins University · USWashington University in St. Louis · USCalifornia Institute of Technology · USUniversity of Miami · USYale University · USBrigham and Women's Hospital · USExosome Diagnostics (United States) · USNational Cancer Institute · USRice University · USScintillon Institute · USUniversity of Chicago · US

Funding

The role of microvesicles in giloma virotherapyP01CA069246 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHIOCCA, E. ANTONIO · 1996 to 2021
$30.9M
EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer AssessmentU01CA233370 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., HSU, WILLIAM · 2018 to 2025
$8.0M
Liquid Biopsy for treatment stratification of IDH1.R132H and EGFRvIII mutant gliomasU01CA230697 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CARTER, BOB S, SKOG, JOHAN · 2018 to 2022
$4.0M
Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with NanoplasmonicsU01CA233360 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CASTRO, CESAR M, DINULESCU, DANIELA M · 2018 to 2022
$3.5M
Clinical platform for high-throughput analyses of extracellular vesiclesR01CA229777 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LEE, HAKHO, SKOG, JOHAN · 2018 to 2022
$3.2M
Imaging and Liquid Biopsy for Glioma Diagnosis and Treatment MonitoringR01CA239078 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BALAJ, LEONORA, LEE, HAKHO · 2020 to 2024
$3.1M
Standardized Molecular Analyses of Glioma EVsR01CA237500 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CARTER, BOB S, LEE, HAKHO · 2020 to 2024
$3.0M
NCI NIH HHS P01 CA069246NCI NIH HHS R01 CA229777NCI NIH HHS R01 CA237500NCI NIH HHS R01 CA239078NCI NIH HHS U01 CA230697NCI NIH HHS U01 CA233360NCI NIH HHS U01 CA233370
6 · The paper itself

Abstract

The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.

Indexed as

Cell-Free Nucleic AcidsExtracellular VesiclesNeoplastic Cells, CirculatingBiomarkersHumansLiquid BiopsyBiomarkersCell-Free Nucleic Acids

Identifiers

PMID37716353
PMCPMC10591039
OpenAlexW4386769281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.